Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.57 USD

201.57
1,465,839

+1.10 (0.55%)

Updated Nov 5, 2024 12:53 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.

Regeneron Expands Agreement to Develop Coronavirus Therapy

by Zacks Equity Research

Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.

Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $82.30, marking a +1.58% move from the previous day.

Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up

by Zacks Equity Research

Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.

Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study

by Zacks Equity Research

Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.

Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat

by Zacks Equity Research

Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.

J&J (JNJ) Plans to Develop Vaccine for New Coronavirus

by Zacks Equity Research

J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.

Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates

by Zacks Equity Research

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $83.77, moving -0.3% from the previous trading session.

Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger

by Zacks Equity Research

Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.

3 Top Dividend Stocks to Maximize Your Retirement Income - January 27, 2020

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

The Market Timing Secrets No One Talks About - January 27, 2020

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q4 Earnings?

by Sweta Killa

With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.

How Trading Your Own Retirement Can Fleece Your Financial Future - January 23, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $87.20, marking a -0.9% move from the previous day.

J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

by Zacks Equity Research

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Simple Secrets Anyone Can Use to Reach Early Retirement - January 22, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe

by Zacks Equity Research

Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - January 20, 2020

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Retirees Should Know These 3 Facts About Required Minimum Distributions - January 17, 2020

by Zacks Equity Research

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

by Kinjel Shah

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

Benjamin Rains headshot

3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio

by Benjamin Rains

Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...